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The Drug Research Board of the Na-
tional Academy of Sciences-National Re-
search Council convened a Conference on 
Clinical PhannacoIogy in Washington, 
D. C., on December 3 and 4, 1970.<'J For 
two days the participants reviewed the 
status and future possibilities of Clinical 
Pharmacology. In some instances the view-
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points of several individuals blended wen 
in support of an idea, while a clear separ-
ation occurred on the other occasions<'J The 
Conference thus afforded an opportunity 
to gauge the state of opinion on many 
important issues related to clinical phar-
macology. 
As Elliott pointed out, recorded interest 
in therapy extends as far back as Sumerian 
tablets. Although the Conference con-
cerned itself largely with the present and 
future, quotations from Aristotle, Spenser, 
Oliver Wendell Holmes, Thoreau, and the 
Chicago Tribune occurred at one time or 
another during the two days. The ability 
to bring Thoreau and the Chicago Tribune 
together in one program is perhaps em-
blematic of the breadth of interest of 
clinical pharmacologists. 
For those who consider the sul£ona-
mides to be the class of drug that initiated 
modern pharmacology, Zubrod's presenta-
tion was appropriate. He traced the grow-
"In preparing this commentary I have been greatly 
aided by additional notes of the Conference taken by 
Drs. Daniel Azamo/I, Henry Elliott, and Kenneth Melmon. 
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725 
726 Carr 
ing interest of Perrin Long and E. K. Mar-
shall, who were so intimately involved 
with chemotherapy of infection during the 
sulfonamide era, in the development of 
clinical pharmacology as an area of teach-
ing, research, and patient care at Johns 
Hopkins University during the period 
1946 to 1953. This interest culminated in 
the establishment of a regular clinical 
pharmacology program under Dr. Louis 
Lasagna in 1955. This was an important 
advance for clinical pharmacology, second 
only to the studies of cardiac glycosides 
in man by Drs. Harry Gold and Walter 
Modell, who were the clinical pharmacol-
ogy pioneers of this century. 
In the present 1970 Conference, Pelikan 
noted that the clinical pharmacologist is 
still easier to define than his field. Burns 
suggested that clinical pharmacology may 
best be defined as the study of drug ac-
tions in man. In the course of his plea to 
avoid isolating clinical pharmacology 
training from the training of basic pharma-
cologists and toxicologists, Pelikan stated 
that all these individuals are engaged in 
the systematic study of the interaction of 
drugs with living organisms; clinical 
pharmacologists study drugs that have 
somewhat more immediate reference to 
health, using systems that more closely 
imitate the intended use of the com-
pounds in medicine. Lee, reviewing the 
activities of clinical pharmacologists in 
Veterans Administration Hospitals, stated 
that he still has difficulty in defining 
clinical pharmacology precisely. Questions 
of definition will apparently continue to 
trouble this interdisciplinary activity for 
many years. 
Nevertheless, the participants agreed 
widely with Goldberg's statement, made 
early in the Conference, that disagree-
ments about definition occupy less atten-
tion than formerly. Previous conferences 
had revealed great concern about the 
"image" of clinical pharmacology, and 
even its viability. Such auxiety was much 
less evident in the early phase of the 
present Conference. Pelikan's concern for 
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the training of larger numbers of basic 
pharmacologists as well as clinical phar-
macologists received support ( Hodges), 
and the definition of pharmacology itself 
was a pertinent topic. Maren defined 
pharmacology as the study of the inter-
action of drugs with large molecules. In a 
previous meeting of training grant direc-
tors, held under the auspices of the National 
Institute of General Medical Sciences (NI 
GMS) in San Francisco in 1969, the defini-
tion of pharmacology itself had also been 
discussed. At that time Dr. Walter Riker 
had stressed selective toxicity as the most 
central concern of pharmacology, with dose-
response and time-action curves as two of 
its most characteristic ways of treating 
data. 
The realization that the increase in new 
drugs calls for increasing atttention to 
clinical pharmacology led to many intra-
mural and extramural clinical pharmacol-
ogy activities at the National Institutes of 
Health ( NIH) . Clark reviewed those 
established by NIGMS and noted that im-
portant support has also been given by 
two other institutes, the National Heart 
and Lung Institute (NHLI) and the Na-
tional Cancer Institute (NCI). In the in-
tramural programs of the NIH the most 
effective obstetrician for clinical pharma-
cology has been Sjoerdsma. In the period 
1958 to 1964 he explored an extensive 
series of new compounds in man and in 
the course of doing this delivered an 
astonishing number of trained individuals 
into the world. The graduates of his pro-
gram are directors and staff members of 
other clinical pharmacology programs all 
over the country. Burns and Hodges added 
their strong support to his view that the 
investigation of new compounds in man is 
the most essential activity of the clini-
cal pharmacologist. 
Extramural direct support of clinical phar-
macology from NIGMS began at Oklahoma, 
although NIGMS had already been sup-
porting clinical pharmacology indirectly 
in programs at Cornell, Penn, California, 
Southwestern, and Michigan before that 
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time. (The program at Oklahoma fostered 
many studies of new compounds in man 
under the excellent direction of the late 
Dr. John Colmore, whose recent death was 
noted with sadness by the conferees.) Sup-
port of clinical pharmacology by NHLI 
(at that time National Heart Institute) 
began early in the last decade at Emory, 
Johns Hopkins, and Michigan. Clark noted 
that annual training program support for 
clinical pharmacology is now approximate-
ly $306,000 (6 programs) from NIGMS, 
$310,000 (6 programs) from NHLI, and 
$124,000 (3 programs) from NCI. Cancer 
chemotherapy, like anesthesiology, may 
be considered as one of the purest forms 
of clinical pharmacology, as Zubrod and 
Elliott, respectively, reminded the Con-
ference. The Pharmacology-Toxicology 
Programs of NIGMS now provide about 
$18,000,000, of which 3 to 4 million go 
to centers and large program projects. In 
addition to direct support of clinical phar-
macology by NIGMS, there is important 
indirect support through programs which 
are not entirely clinical pharmacology 
but still have an important clinical 
pharmacology component. Approximately 
$5,000,000 of the total support of clin-
ical research centers throughout the 
country may be considered support of 
activities in the clinical pharmacology 
area. Certain activities of NHLI and NCI 
may be considered indirect support of 
clinical pharmacology, somewhat analo-
gous to that given by NIGMS. In answer 
to a question from the audience, it was 
stated that a considerable amount of 
medical school teaching, including post-
graduate teaching, receives indirect sup-
port from the numerous NIH funds mem-
tioned above, although the medical 
schools themselves may not always take 
the best advantage of the possibilities of-
fered to them in this regard. 
Winter described support of clinical 
pharmacology by the Pharmaceutical 
Manufacturers Association (PMA), as he 
reviewed the history of programs that be-
gan in 1965. Nineteen faculty develop-
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ment awards have been given, as well as 
a wide variety of other types of support, 
including fellowships for medical students, 
etc. In addition to support by PMA as a 
group, at least ten companies support 
clinical pharmacology through some form 
of individual effort. Earlier in the Con-
ference Elliott had mentioned that one 
possible solution to the problera of finding 
sufficient space for clinical pharmacology 
in various medical centers was the housing 
of all clinical pham1acology activities in 
one building devoted entirely to this field 
and had used the Upjohn Center at 
Michigan as an example. Richardson dis-
cussed the need for clinical pharmacology 
groups to have their own financial support, 
space, recruiting program, and research 
program, although he did not favor the 
establishment of clinical pharmacology 
groups as separate departments. Such an 
interdisciplinary activity, not based in any 
single department, requires strong support 
from the dean's office in each medical 
school. In making this last point, Richard-
son was reiterating a major conclusion of 
the Basin Harbor Conference of 1965. Al-
though little support for the idea of 
separate clinical pharmacology depart-
ments was expressed by anyone at the 
present Conference, the concept of clinical 
pharmacology as a specialty in itself pro-
voked some debate. Cooper supported this 
concept, while Zubrod questioned it. 
Thus far one may have the picture of 
a group moderately pleased with its own 
progress in overcoming severe problems 
that had been apparent as recently as five 
years ago and fairly hopeful that the 
modus vivendi between clinical pharma-
cology and basic pharmacology, so recent-
ly developed, would prove workable. 
But any complacency about this last sug-
gestion was broken by a loud "nyet" from 
Leaf. In a calm, quiet presentation Leaf 
gave the most provocative talk of the 
Conference. He claimed that the increase 
in number of drugs, which has recently 
received so much attention, really means 
an increase in the need for subspecialists 
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to teach about their specific classes of 
drug in the setting of a good clinical de-
partment. Leaf feels that good clinical de-
partments are the places in which one 
finds the best research in the use of drugs. 
He believes that quality control can best 
be achieved by having clinical pharma-
cologists in subspecialty units. As to the 
fate of pharmacology departments them-
selves, they may continue to exist or, al-
ternatively, a consortium of clinicians en-
gaged in good drug research may re-
place the traditional activities of a phar-
macology department, he suggested. 
Though no other speaker supported Leaf's 
proposal in toto, many comments of other 
speakers could be interpreted as consistent 
with Leaf's thesis. Oates stressed the im-
portance of good clinical training for 
clinical pharmacologists, and Richardson 
called further attention to the large 
amount of good clinical pharmacology 
performed by people who do not call 
themselves clinical pharmacologists. Per-
haps the lack of any formal affiliation with 
pharmacology is not very harmful after 
all, Richardson added. Railman estimated 
that about 85 per cent of the clinical 
pharmacology required by industry is at 
present conducted by specialists who do 
not call themselves clinical pharmacol-
ogists, and Papper referred to many clini-
cal pharmacologists as "internists in dis-
guise." Gurley observed that it is easier 
to convert an M.D. into a pharmacologist 
than to convert a Ph.D. into a clinician 
and added that some basic scientists are 
now leaving their bases in medical schools 
to join undergraduate university depart-
ments. Maren admitted that close relation 
to pharmacology does indeed slow the re-
cruiting of clinical pharmacologists. Even 
course work may not require a department 
for its organization; Gurley emphasized 
that many courses are now planned by 
committees rather than departments ( a 
development that Bass deplored). At 
present many clinical pharmacologists do 
not have "the security of an organ sys-
tem," in Oates' phrase, and are often ill 
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at ease with basic pharmacologists, ac-
cording to Freedman and Papper. Papper 
also described the worries of many clinical 
pharmacologists about possible loss of 
clinical skills if too much time is spent in 
basic pharmacology. All 36 clinical phar-
macology programs described in Azarnoff's 
report to the Conference have relations 
with the departments of internal medicine, 
and one may therefore assume that such 
departments prOVide a reasonable environ-
ment for clinical pharmacology. Pharma-
cology itself is often considered irrelevant 
by students, Whitsett stated. 
But comments in opposition to Leaf's 
ideas were even more frequent than those 
supporting him. Maren stated that his 
pharmacology department had developed 
a good clinical pharmacology program and 
clinicians have been happy to have this re-
lation with pharmacology. The panel 
method of teaching provides an opportu-
nity to bring clinicians and pharmacologists 
together in his program. One of the strong-
est arguments used against Leaf was the 
point that many clinicians ignore the core 
knowledge of chemistry, absorption, distri-
bution, metabolism and excretion of drugs, 
dose response, etc., that are essential to any 
pharmacology, clinical or otherwise. In one 
form or another this statement was made 
by Maren, Papper, Freedman, Melmon, 
Whitsett, Oates, Cooper, and Hailman. 
Oates, Burns, and Melmon were particu-
larly careful to identify the common de-
nominator uniting clinical pharmacologists 
and requiring participation of a pharma-
cology department. Dose-response rela-
tions, comparative potency, interactions be-
tween drugs, drug disposition, the relation 
between the concentration of a drug in the 
plasma and its effect, genetic factors, etc., 
were all included. 
Burns added that pharmacogenetics and 
immunopharmacology represent promising 
areas for basic pharmacologists to enter and 
unite more strongly with clinical pharmacol-
ogy. Freedman, Winter, and Papper all ex-
pressed confidence that the clinical pharma-
cologist who feels ill at east in the basic 
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pharmacology department need not remain 
that way if proper steps are taken. Richard-
son and Freedman warned against the lack 
of flexibility that might follow if clinical 
pharmacology were tied to one clinical 
group. Papper and Gurley emphasized the 
need for teaching in pharmacology to be 
strongly oriented toward clinical pharma-
cology (echoing an earlier statement of 
Oates that teaching must not be secondary 
to any other consideration in the mind of 
a clinical pharmacologist), but once the 
importance of clinical problems is ac-
cepted by a pharmacology department, 
clinical pharmacologists should be related 
to basic pharmacology "without compro-
mise." Papper and Gurley felt that the 
interfaces between clinical pharmacology 
and the various clinical specialties will be 
best preserved by basing clinical pharma-
cology in a pharmacology department. The 
interface with pediatrics received special 
attention after Palmisano took clinical 
pharmacologists to task for neglecting this 
important area. However, Mirkin described 
a strong relation between clinical pharma-
cology and pediatrics at Minnesota, and 
Azarnoff's report indicated that 11 clinical 
pharmacology programs include participa-
tion of pediatrics departments. Other inter-
faces receiving particular attention during 
the Conference were those with anesthesi-
ology (Elliott), industry (Nance), psychi-
atry (Burns and Freedman), and toxicol-
ogy (Gurley). Melmon described an inter-
esting program in which clinical pharma-
cology cooperates with a research group 
in pharmacy that provides expertise in 
pharmacokinetics, organic chemistry, 
mathematics, and drug assays in body tis-
sues. 
At the same time, Melmon urged clin-
ical pharmacologists to abandon the "octo-
pus concept" that would require them to 
be involved in a huge number of simul-
taneous activities, almost without limit. In 
this regard Martz felt that efficacy reviews 
of large numbers of drugs might waste 
huge amounts of clinical pharmacologists' 
time. Oates, Maren, and Elliott all agreed 
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that a pharmacology department is cer-
tainly the best place in which to put a 
clinical pharmacology training program. 
Thirty-five of the 36 programs reviewed 
by Azamoff have at least some relation to 
basic pharmacology departments. New 
compounds, which Burns termed the life-
blood of clinical pharmacology, are more 
likely to be studied by programs that have 
close relations to pharmacology depart-
ments, though it must be admitted that 
some pharmacology departments do not 
currently have a very impressive record in 
this regard. The important role of industry 
in providing such new compounds was 
emphasized by Hodges. Indeed, the ex-
citement that comes from an important 
effect of a new compound in man is prob-
ably the strongest attraction of clinical 
pharmacology, an attraction that Sjoerds-
ma, Bums, and Hodges all listed as para-
mount. The admittedly rare success of this 
type makes all the other work (including 
much dull routine) worthwhile. In a final 
attack on Leaf's thesis, Hailman observed 
that clinical specialists of the type men-
tioned by Leaf are best qualified to do the 
type of study that the pharmaceutical in-
dustry least needs. In summary, Leaf 
served the Conference well. By avoiding 
the soap-boxery so often used by challeng-
ers, he set a tone of rational discussion 
rather than heated argument. But his pro-
posals received extensive criticism. 
But clinical pharmacology must be 
afflicted with other problems for, as Pap-
per stated, this field is not flourishing as 
it should. Training programs that last only 
one year are too short to contribute much 
to the field, in the opinion of Maren, Oates, 
and Azarnoff. Oates mentioned the diffi-
culty in reaching members of the house 
staff in medical centers; Whitsett explained 
that the attitude of many clinicians who 
considered diagnosis far more important 
than therapy is transmitted to the house 
staff. Gilman added that adverse ideas 
about the pharmaceutical industry and its 
products filter down from the United States 
Congress all the way to medical students. 
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The pharmaceutical industry is ground be-
tween governmental regulations (a com-
plaint of Martz, Gilman, Hailman, and 
Sjoerdsma) and the aloof attitude of many 
clinical pharmacologists (a complaint of 
Martz, Nance, and Hailman). Edwards 
and Finkel defended the Food and Drug 
Administration while Oates and Azarnoff 
defended clinical pharmacologists, respec-
tively, against the two speciRcations of the 
above charge. As a representative of the 
phannaceutical industry who also has a 
very long record of interest in clinical 
pharmacology training, Kohlstaedt was in 
the least controversial position during this 
argument. 
Sjoerdsma gave one of the most emphatic 
talks of the Conference as he reviewed 
various dismal experiences with regula-
tions. He seriously suggested emigration to 
Europe as a possible solution. This sug-
gestion led Gross to warn against con-
sidering Europe as any Utopia for clinical 
studies. Although RaIl noted that some 
types of study are more easily carried out 
in England than in the United States, 
Hodges predicted that this favorable (to 
England) difference might be more appar-
ent than real and, in any event, transitory. 
In a comment from the audience, Dr. W. 
J. R. Taylor asked the Conference to con-
sider ways to ease the heavy burden of 
Congressional pressure on the FDA and 
to provide some mechanism whereby the 
FDA can perform a positive function rather 
than merely a negative, regulatory func-
tion. As Oates and Sjoerdsma agreed, the 
FDA has had trouble with its own image 
and this has certainly been no help to 
clinical pharmacology in general. 
The public (and its lawyers) accept the 
benefits associated with new drugs, but 
they are unwilling to accept the inevitable 
hazards associated with the use of effective 
drugs. In making the last comment, Martz 
did not confine his criticism to the FDA. 
He added that "budget time is a bad time 
for clinical pharmacology in most schools." 
As Oates and Papper reminded the Con-
ference, clinical phannacologists do not 
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have the same source of clinical income 
as most other clinicians, and this problem 
adds to the financial woes of clinical phar-
macology. Thus, manpower in the field 
remains short and recruiting continues to 
be difficult (Oates). Pelikan and Hodges 
added that recruitment for all pharma-
cology, not simply clinical pharmacology, 
should concern the Conference. 
Azarnoff reported results of a survey 
taken under the auspices of the American 
Society for Pharmacology and Experimen-
tal Therapeutics, indicating that 101 out 
of 131 training positions in clinical pharma-
cology were RIled at the time of the sur-
vey. A second survey suggests that medical 
schools now have about 120 full-time clin-
ical pharmacologists, with approximately 
100 more devoting a considerable part of 
their time to this activity, but Azamoff 
gave reasons for conSidering this Rgure an 
over-estimate. By 1980, each medical 
school, according to its currently listed 
needs, will require for the staffing of its 
clinical phannacology programs about Rve 
more individuals than it is likely to get, at 
the current rate of production of clinical 
pharmacologists. Clark's Rgures suggested 
a need for 500 clinical pharmacologists 
within the next few years, with perhaps 
250 as a realizable goal by 1976. Hodges 
felt that at least 200 would be needed, 
whereas Hailman predicted a much greater 
requirement than the above Rgures would 
suggest. 
The most signilicant aspect of the various 
projections and estimates was their con-
sensus that the output of clinical pharma-
cologists, at the current rate of produc-
tion, will fall far below the need. Yet, as 
Freedman, Bass, and others repeated, the 
climate is not salubrious for clinical phar-
macology or indeed for other types of 
advanced teaching and research at the 
present moment. The demand for health 
care is increasing, while the funding of 
much research and teaching is decreased. 
Moreover, there is strong pressure to train 
physicians more quickly and thus increase 
the number of practicing physicians. An 
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increased number of physicians, faced with 
an increased number of individuals de-
manding health care, will probably react 
with an inordinate increase in the prescrib-
ing of drugs. In such an environment, the 
failure to provide for increased teaching 
of clinical pharmacology at all levels of 
medical education will be especially dam-
aging. We may return to the situation 
described by Moliere, when, according to 
one of his characters, most people were 
dying of their remedies rather than their 
maladies. 
Not all clinical pharmacology activities 
have happy endings, and Elliott candidly 
described discouraging experiences with 
a "pain clinic"; one might say it turned 
out to be more of a pain than a clinic. But 
Elliott stressed that such examples can 
hardly serve as an indictment of the whole 
field. If "the ability to use drugs wisely is 
a good test of a physician" (Lee), many 
schools are not preparing their students 
to pass this test. 
Palmisano felt that clinical pharmacol-
ogists themselves had failed in their re-
cruiting of pediatricians, for less than 15 
per cent of pediatric departments have any 
individuals with a joint appointment in 
pediatrics and pharmacology. However, 
Mirkin, as noted above, described an im-
portant pediatric-clinical pharmacology re-
lation at Minnesota. Many studies which 
might be considered pedestrian and call-
ing for little talent on the part of the in-
vestigator when carried out in adults are 
important, difficult, and a major challenge 
to any investigator's ingenuity when the 
subjects are infants or children. Bums, 
Christensen, and Palmisano described sev-
eral of the special problems of methodol-
ogy, including number of available sub-
jects, informed consent, and translation of 
data from animals to man. Pharmacokinetic 
studies are greatly needed in the pediatric 
age groups (Azarnoff). 
The status of clinical pharmacology thus 
appeared reasonably healthy when studied 
with a low-power lens but much less en-
couraging when examined under higher 
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magnification. Many suggestions for im-
provement were made during the course of 
the two days. Oates outlined an important 
mechanism in which superior teaching as 
well as research can establish a positive 
feedback, with greater knowledge of clin-
ical pharmacology attracting greater num-
bers of trainees who may themselves 
subsequently become teachers. He men-
tioned conferences, rounds, rotating assign-
ments of house staff to clinical pharmacol-
ogy programs, etc., as possible mechanisms 
to improve instruction but warned against 
accepting the value of any specific teach-
ing method in this area until the method 
has been evaluated. (If such evaluations 
have been carried out, they must be very 
well-kept secrets, it appears.) 
Whitsett suggested that activities of 
clinical pharmacologists, including counsel-
ing of other investigators in experimental 
deSign, serving as reference sources for 
information about many drugs, and pro-
viding expertise in the study of adverse 
reactions, are still underdeveloped. He re-
called the statement of the late Dr. John 
Colmore, a leader in early-phase studies 
of new compounds in man, that clinical 
pharmacologists should be first of all lead-
ers in the evaluation of new drugs. Clark 
and Nance agreed strongly with Whitsett's 
presentation and discussed various possi-
bilities of providing increased support for 
such studies of new drugs. 
Whitsett called on clinical pharmacol-
ogists to improve their teaching of stu-
dents, especially to improve their students' 
ability to interpret the extensive literature 
and advertisements concerned with drugs. 
Bums noted that clinical pharmacologists 
might well teach many other investigators 
some of the facts of life in this regard. 
Martz suggested that therapeutics should 
perhaps be restored to the medical curricu-
lum as a subject in its own right. Although 
courses given in the last year of medical 
school give medical students their most eas-
ily identifiable exposure to clinical pharma-
cology (Oates), exposure during all four 
years of medical school would be desirable 
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(Papper). Clinical pharmacologists are do-
ing increasing amounts of teaching of basic 
pharmacology (Gurley) while increasing 
their participation in such areas as poison 
control, etc. Hodges and Papper joined 
Gurley in the conclusion that one must use 
skilled teachers of pharmacology wherever 
they may be found, whether in basic or 
clinical pharmacology groups. It was 
widely agreed that clinical pharmacology 
must continue to be concentrated in one 
administrative unit and that this unit-
regardless of specific arrangements in any 
given medical center-must have a base 
in pharmacology and important relations 
with clinical specialties such as internal 
medicine. Finkel and Cooper both held 
out hope that some of the regulatory prob-
lems associated with drug research may les-
sen in the near future. Although the Con-
ference members warmly welcomed this 
hope and also credited its proponents with 
charity, many in the Conference appeared 
to lack faith in this matter. Legislation may 
actually grow more, rather than less, strict 
unless mechanisms for peer review of drug 
therapy are established (Freedman) . A 
steady increase in restrictive legislation is 
already visible (Sjoerdsma). 
Goldberg suggested that lack of funds 
has probably replaced lack of clear image 
as the biggest single problem facing clin-
ical pharmacology. Clinical pharmacology 
need not plan an expansion into every 
medical school in the country overnight in 
order to make advances, but increased 
financial support is essential (Oates, Bums, 
Richardson) . Clark and Freedman dis-
cussed the possibility of further support 
through a career investigator program; 
Oates reiterated the need for long-term 
salary support, a need that is now under 
study by the PMA (Winter). Zubrod sug-
gested special awards to increase the num-
ber of pediatric clinical pharmacologists. 
Bums described current industrial support 
of certain clinical pharmacology units 
which are are not based in medical schools 
but do everything a medical school clinical 
pharmacology unit does, using the facilities 
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of non-university hospitals. He believes 
that industrial support will be needed in-
creasingly not only for clinical pharmacol-
ogy but also for basic pharmacology. Hail-
man, however, felt that this entire area of 
support is a problem for government more 
than industry. Maren felt it essential that 
schools themselves increase their funding, 
while Papper focused the call for support 
onto clinical departments. The present level 
at which many trainees' stipends are fixed 
by law is a serious problem (Clark). 
The spatial constraint under which 
many clinical pharmacology programs 
operated was so pressing in 1965 that it 
received italic emphaSis in the report of 
the Basin Harbor Conference. Martz re-
minded the 1970 Conference that this need 
still exists in many medical centers, al-
though solutions have been achieved in 
some. Maren supplies the space for clinical 
pharmacology in the pharmacology de-
partment. Elliott agreed that there are 
advantages in providing clinical pharma-
cology with its central space in a pharma-
cology department, provided the clinical 
pharmacologists have joint appointments 
with their appropriate clinical departments 
and are thus frequently present in the 
clinical areas. He pOinted out that a clinical 
pharmacology division which has its main 
physical base in a department of internal 
medicine provides certain difficulties for 
other clinical disciplines that wish to par-
ticipate in the clinical pharmacology pro-
gram. 
A succinct description of the type of 
individual that clinical pharmacology 
wishes to recruit was given by Zubrod, as 
he described the qualities that the Bur-
roughs Wellcome Foundation sought in its 
candidates: scientific ability, clinical abil-
ity, leadership ("spark and imagination"), 
a real interest in the fate of drugs and 
normal compounds in man, ability to "carve 
out a place" in his own school, plus the 
motivation and ability to be a teacher. 
These criteria created a successful selec-
tion system, for the schools to which suc-
cessful candidates have gone are clearly 
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showing a continued interest in the teach-
ing and practice of rational therapy of 
diseased people. Cooper described six 
different areas in which governmental pro-
grams require clinical pharmacologists 
and, in my opinion, gave one of the best 
answers ever made to the implied question: 
How can anyone be a clinical pharmacol-
ogist, since he cannot be an expert in the 
use of every drug? Cooper pointed out 
that a clinical pharmacologist can serve 
as a "resident expert" who admittedly is 
not the final expert for each drug but can 
nevertheless ask the right questions and 
stimulate the work that will provide their 
answers. Cooper did not feel that some 
form of certification of clinical pharmacol-
ogists should necessarily be dismissed as 
a poor idea. His presentation also reminded 
the Conference that the prophylactic trial 
is as much a part of clinical pharmacology 
as the therapeutic trial. 
Cooper, Lee, Kohlstaedt, and Zubrod all 
gave examples of the need for more multi-
center trials. Elliott and Palmisano sug-
gested that professional societies have not 
been sufficiently involved in clinical phar-
macology activities. The safety aspect 
which Edwards expressed as a major con-
cern of the FDA might be better served 
Conference on clinical pharmacology 733 
if relatively simple, early studies received 
more attention, in defiance of present 
academic insistence on elegant studies as 
the only acceptable type. Hailman termed 
such simple, early studies "clinical sharp-
shooting"; Gilman and Gross agreed that 
simplicity should not automatically be con-
sidered a vice, with the crown of virtue 
reserved for complicated studies alone. A 
system of local peer review might replace 
some FDA regulations (Sjoerdsma), but 
local review is not likely to be any panacea 
for the stifling effects of regulations. 
As Goldberg noted at the end, the short-
age of clinical pharmacologists remains: 
both the "genetically pure" type described 
by Gilman and the specialty-oriented 
clinician who conducts good clinical in-
vestigations with drugs are needed in larg-
er numbers. The major site of training must 
continue to be medical schools. To in-
crease the number of clinical trials con-
ducted in academic institutions, every 
medical school will probably need at least 
five additional clinical pharmacologists. 
Clinical pharmacologists, while maintaining 
their own units, must also work to reverse 
the trend of disappearing pharmacology 
departments in some medical schools. 
